We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET Imaging and Bariatric Surgery

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00801827
First Posted: December 4, 2008
Last Update Posted: March 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Julia P.Dunn,MD, Vanderbilt University Medical Center
  Purpose
The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.

Condition Intervention Phase
Obesity, Morbid Drug: F-18 (fallypride) Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: PET Imaging and Bariatric Surgery

Resource links provided by NLM:


Further study details as provided by Julia P.Dunn,MD, Vanderbilt University Medical Center:

Primary Outcome Measures:
  • Regional DRD2/3 Binding Percent Changes After Bariatric Surgery [ Time Frame: ~7 weeks ]

Enrollment: 7
Study Start Date: January 2007
Study Completion Date: June 2012
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: F-18 (fallypride)
Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET) scans of their brains using F-18 (fallypride), a dopamine type 2/3 (DA D2/3) receptor radioligand whose binding is sensitive to competition with endogenous dopamine, before and after the operation.
Drug: F-18 (fallypride)
Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.

Detailed Description:
The purpose of this study is to look at certain areas of the brain that are related to addictive behaviors, such as overeating. These areas are called 'dopamine type 2 receptors' (DRD2/3) and other studies have shown that obese people have less of these. We propose that low DRD2/3 availability seen in morbidly obese subjects will change with weight loss associated with bariatric surgery.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages 18-60 years
  • BMI equal to or greater than 40, or equal to or greater than 35 if there are 2 or more co-morbidities
  • Weight less than 350 pounds

Exclusion Criteria:

  • History of substance abuse,including but not limited to alcohol, cocaine, marijuana, heroin, nicotine
  • History of psychiatric disorders
  • Use of any antidepressants or psychotropics in the past 12 months
  • Diabetes Mellitis
  • Positive pregnancy test
  • Any condition felt by the PI or co-investigators to interfere with the individual's ability to complete the study
  • Subjects on medications for the last 3 months, such as sibutramine, which could affect the quality of the study, as determined by the PI
  • Inability to travel to Nashville, TN four times
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00801827


Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University Medical Center
Investigators
Principal Investigator: Julia P Dunn, MD Vanderbilt University Medical Center
Study Director: Robert M Kessler, MD Vanderbilt University Medical Center
  More Information

Responsible Party: Julia P.Dunn,MD, Physician, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier: NCT00801827     History of Changes
Other Study ID Numbers: IRB#061246
First Submitted: December 2, 2008
First Posted: December 4, 2008
Results First Submitted: August 22, 2016
Results First Posted: March 17, 2017
Last Update Posted: March 17, 2017
Last Verified: January 2017

Keywords provided by Julia P.Dunn,MD, Vanderbilt University Medical Center:
Obesity
Addiction
PET imaging

Additional relevant MeSH terms:
Obesity, Morbid
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms